Art. -Nr.: HY-10459

PF-562271

(Synonyms: VS-6062)

32 Cited Publications

Kundenbewertung

Based on 32 publication(s) in Google Scholar

PF-562271 (VS-6062) is an orally active, ATP-competitive, reversible FAK/Pyk2 inhibitor, with an IC₅₀ of 1.5 nM for FAK and 13 nM for Pyk2. PF-562271 induces tumor regression, and inhibits tumor growth, invasion and metastasis. PF-562271 exerts no effect on tumor necrosis, angiogenesis or apoptosis in an orthotopic mouse model of pancreatic ductal adenocarcinoma. When combined with Sunitinib (HY-10255A), PF-562271 reduces tumor vascularization, decreases serum alpha-fetoprotein levels and improves cachexia. PF-562271 can be used in research related to prostate cancer, breast cancer, pancreatic cancer, colon cancer, glioblastoma, lung cancer, pancreatic ductal adenocarcinoma and hepatocellular carcinoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.36%
CAS. Nr.: 717907-75-0
Formel: C₂₁H₂₀F₃N₇O₃S
Molecular Weight:507.49

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

PF-562271 Chemical Structure

CAS. Nr.: 717907-75-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (32)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
A375P	GI₅₀	10.22 μM Compound: PF-562271	Antiproliferative activity against human A375P cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human A375P cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
HCT-116	GI₅₀	1.14 μM Compound: PF-562271	Antiproliferative activity against human HCT-116 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human HCT-116 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
MDA-MB-231	GI₅₀	1.95 μM Compound: PF-562271	Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay	[PMID: 34324343]
Sf21	IC₅₀	13 nM Compound: PF562271	Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells	[PMID: 27876318]
Sf9	IC₅₀	1.5 nM Compound: PF562271	Reversible/competitive inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP Reversible/competitive inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP	[PMID: 27876318]
SMMC-7721	IC₅₀	23.92 μM Compound: PF-562271	Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 34214842]

In Vitro

PF-562271 potently inhibits purified recombinant FAK (with an IC₅₀ of 1.5 nM) and recombinant Pyk2 (with an IC₅₀ of 13 nM) via ATP-competitive reversible binding^[1].
PF-562271 exhibits over 100-fold selectivity against most tested non-target recombinant kinases, and only shows moderate activity against a subset of cyclin-dependent kinase complexes^[1].
PF-562271 (starting concentration of 1 μM; 30 min) potently and suppresses the autophosphorylation of FAK^Y397 in A431 epithelial cancer cells with an IC₅₀ of 5 nM^[1].
PF-562271 (1.1-3.3 μM; 48 h) alters the cell cycle progression of PC-3M cells only after incubation at the high concentration of 3.3 μM for 48 h^[1].
PF-562271 is an ATP-competitive reversible inhibitor that potently inhibits the kinase activities of purified recombinant FAK (IC₅₀ = 1.5 nM) and PYK2 (IC₅₀ = 14 nM)^[2].
PF-562271 (0.1 μM) significantly inhibits IGF-I-stimulated chemotactic migration of the PDA cell line MPanc-96, but does not affect EGF-stimulated migration of this cell line^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA Assay^[1]

Cell Line:

Inducible stable A431 epithelial carcinoma clones expressing wild-type V5-tagged FAK
Concentration:

1 μmol/L (starting concentration, serially diluted)
Incubation Time:

30 min
Result:

Inhibited FAK^Y397 autophosphorylation with an IC₅₀ of 5 nmol/L (2.5 ng/mL).
Showed ~4-fold lower potency for Pyk2 in comparative cell assays.

Cell Cycle Analysis^[1]

Cell Line:

PC-3M human prostate cancer cells
Concentration:

1.1 μmol/L; 3.3 μmol/L
Incubation Time:

48 h
Result:

Reduced the percentage of cells in S and G2-M phases to levels comparable to serum-starved cells at 3.3 μmol/L.
Exerted no effect on cell cycle progression at 1.1 μmol/L.

In Vivo

PF-562271 (3.3-33 mg/kg; p.o.; single dose) inhibits tumor FAK phosphorylation in a dose- and time-dependent manner after oral administration, with an EC₅₀ of 93 ng/mL for whole blood concentrations^[1].
PF-562271 (25-50 mg/kg; p.o.; once daily, twice daily; 15 days) induces dose-dependent tumor growth inhibition in PC-3M xenografts. The efficacy of twice-daily administration is superior to that of once-daily administration at the same total daily dose, and the dose of 50 mg/kg twice daily achieves a TGI of 78% accompanied by partial tumor regression^[1].
PF-562271 (50-100 mg/kg; p.o.; twice daily, once daily; continuous delivery via osmotic minipump) induces significant tumor growth inhibition in BxPc3 xenografts, with the 50 mg/kg twice daily dose achieving 86% TGI and partial tumor regression^[1].
PF-562271 (12.5-50 mg/kg; p.o.; twice daily; for 29 consecutive days) induces dose-dependent tumor growth inhibition in BT474 xenografts, with the 50 mg/kg twice-daily dose achieving a 94% TGI accompanied by partial tumor regression^[1].
PF-562271 (33 mg/kg; twice daily) reduces tumor volume, decreases tumor cell proliferation rate, and significantly lowers the incidence of retroperitoneal invasion and metastasis of orthotopic MPanc-96 pancreatic ductal adenocarcinoma in athymic nude mice^[2].
Combination treatment with PF-562271 (15 mg/kg; p.o.; twice daily; 7 days per week) and Sunitinib (HY-10255A) administered at 20 mg/kg four times daily effectively inhibits hepatocellular carcinoma tumor growth in nude mice, reduces serum AFP and AST levels, impairs tumor angiogenesis, and induces tumor necrosis^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

CD-1 Nu/Nu (female, ≈20 grams, U87MG human glioblastoma xenograft model)^[1]
Dosage:

3.3 mg/kg; 10 mg/kg; 33 mg/kg
Administration:

p.o.; single dose
Result:

Achieved 78% maximal inhibition of tumor phospho-FAK at 1 hour postdose, with >50% inhibition sustained for >4 hours (33 mg/kg dose).
Achieved 70% maximal inhibition of tumor phospho-FAK, with >50% inhibition sustained for <2 hours (10 mg/kg dose).
Calculated an EC₅₀ of 93 ng/mL for total blood PF-562271 (mesylate) concentration required for half-maximal reduction of FAK phosphorylation.

Animal Model:

CD-1 Nu/Nu (female, ≈20 grams, PC-3M human prostate xenograft model)^[1]
Dosage:

50 mg/kg (daily); 25 mg/kg (twice daily); 50 mg/kg (twice daily)
Administration:

p.o.; daily; 15 days; p.o.; twice daily; 15 days
Result:

Resulted in 45% tumor growth inhibition (TGI) and 37% inhibition of tumor phospho-FAK after 15 days, with a free Cₘₐₓ of 157 ng/mL (50 mg/kg daily dose).
Resulted in 61% TGI and 27% inhibition of tumor phospho-FAK after 15 days, with a free Cₘₐₓ of 25 ng/mL (25 mg/kg twice daily dose).
Resulted in 78% TGI, 52% inhibition of tumor phospho-FAK after 15 days, regressions in 3/7 mice, a free Cₘₐₓ of 96 ng/mL, and a free Cₐᵥₑ of 16 ng/mL (50 mg/kg twice daily dose).
Caused no weight loss, morbidity, or mortality.

Animal Model:

CD-1 Nu/Nu (female, ≈20 grams, BxPc3 human pancreatic xenograft model)^[1]
Dosage:

50 mg/kg (twice daily); 100 mg/kg (daily); steady-state free concentration of 0.7 ng/mL (continuous delivery)
Administration:

p.o.; twice daily; p.o.; daily; continuous delivery via osmotic mini-pump
Result:

Resulted in 86% TGI, 31% inhibition of tumor phospho-FAK, regressions in 3/10 mice, and a free Cₘₐₓ of 273 ng/mL (50 mg/kg twice daily dose).
Resulted in 71% TGI and 59% inhibition of tumor phospho-FAK, with a free Cₘₐₓ of 705 ng/mL (100 mg/kg daily dose).
Resulted in 57% TGI and 37% inhibition of tumor phospho-FAK (continuous delivery via osmotic mini-pumps).
Caused no weight loss, morbidity, or mortality.

Animal Model:

CD-1 Nu/Nu (female, ≈20 grams, BT474 human breast xenograft model)^[1]
Dosage:

12.5 mg/kg (twice daily); 25 mg/kg (twice daily); 50 mg/kg (twice daily)
Administration:

p.o.; twice daily; 29 days
Result:

Resulted in 37% TGI, 50% inhibition of tumor phospho-FAK, a free Cₘₐₓ of 29 ng/mL, and a free Cₐᵥₑ of 3 ng/mL (12.5 mg/kg twice daily dose).
Resulted in 59% TGI, 55% inhibition of tumor phospho-FAK, regressions in 3/8 mice, a free Cₘₐₓ of 116 ng/mL, and a free Cₐᵥₑ of 14 ng/mL (25 mg/kg twice daily dose).
Resulted in 94% TGI, 76% inhibition of tumor phospho-FAK, regressions in 4/8 mice, a free Cₘₐₓ of 180 ng/mL, and a free Cₐᵥₑ of 40 ng/mL (50 mg/kg twice daily dose).
Caused no weight loss, morbidity, or mortality.

Chemical Information

CAS. Nr. 717907-75-0
Appearance Solid
Molecular Weight 507.49
Formel C₂₁H₂₀F₃N₇O₃S
Color Light yellow to brown
SMILES

CS(=O)(N(C)C1=NC=CC=C1CNC2=NC(NC3=CC4=C(C=C3)NC(C4)=O)=NC=C2C(F)(F)F)=O
Synonyms

VS-6062
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (32)

All WB

Sort by:

Journal Impact Factor

Nat Biomed Eng

Nonexpansive biodegradable matrix promotes blood vessel organoid development for neurovascular repair and functional recovery in ischaemic stroke. [Abstract]

2025 Nov 3. PMID: 41184604
Cancer Res

High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma. [Abstract]

2013 May 1;73(9):2873-83. PMID: 23536552

PF-562271 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2013 May 1;73(9):2873-83. [Abstract]

FAK inhibition downregulates the AKT/mTOR pathway and CAS activity. A, protein levels measured by Western immunoblotting for AKT/mTOR pathway proteins in A673 and TC32 cells serum-starved overnight, treated with PF-562271 for 6 hours, and then stimulated with IGF-1 for 2 hours. Vinculin is used as the loading control. B, Western immunoblots showing downregulation of phospho-CAS but not phospho-ERK in A673 and TC32 cells after treatment with PF-562271.
Autophagy

PTK2/FAK inhibition triggers TMED9-mediated protective autophagy in pancreatic cancer cell via enhancing ERGIC-ERES contact. [Abstract]

2026 May 29:1-15. PMID: 42144738
Cell Discov

A positive mechanobiological feedback loop controls bistable switching of cardiac fibroblast phenotype. [Abstract]

2022 Sep 6;8(1):84. PMID: 36068215
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Carbohydr Polym

Inulin-like polysaccharide ABWW may impede CCl4 induced hepatic stellate cell activation through mediating the FAK/PI3K/AKT signaling pathway in vitro & in vivo. [Abstract]

2024 Feb 15:326:121637. PMID: 38142102
Cell Death Dis

Identification of matrix-remodeling associated 5 as a possible molecular oncotarget of pancreatic cancer. [Abstract]

2023 Feb 24;14(2):157. PMID: 36828810

PF-562271 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2023 Feb 24;14(2):157. [Abstract]

PF-562271 (250 nM; 6 h) largely inhibits Akt-S6 phosphorylation in OE-MXRA5 priPC-1 cells.
Cell Death Dis

P130cas-FAK interaction is essential for YAP-mediated radioresistance of non-small cell lung cancer. [Abstract]

2022 Sep 10;13(9):783. PMID: 36088346
Clin Cancer Res

High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma. [Abstract]

2019 Jul 15;25(14):4552-4566. PMID: 30979745
Int J Surg

Supervising the recurrence of pancreatic ductal adenocarcinoma using CtDNA-based MIR129-2 methylation detection. [Abstract]

2025 Sep 17. PMID: 40961228
Am J Chin Med

Evodiamine Suppresses Lung Cancer Progression Through Modulating FAK/STAT3/AKT Signaling Pathway. [Abstract]

2025;53(4):1225-1240. PMID: 40582716
World J Gastroenterol

FBP1 as a key regulator of focal adhesion kinase-mediated hepatic stellate cell activation: Multi-omics and experimental validation. [Abstract]

2025 Jul 28;31(28):107361. PMID: 40741470
Cell Rep

Mechanotransduction in response to ECM stiffening impairs cGAS immune signaling in tumor cells. [Abstract]

2023 Oct 5;42(10):113213. PMID: 37804510
Life Sci

Harmine inhibits the proliferation and migration of glioblastoma cells via the FAK/AKT pathway. [Abstract]

2021 Apr 1:270:119112. PMID: 33508300
Breast Cancer Res

TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9. [Abstract]

2024 Mar 19;26(1):48. PMID: 38504374
Sci Rep

The mechanical microenvironment regulates ovarian cancer cell morphology, migration, and spheroid disaggregation. [Abstract]

2018 May 8;8(1):7228. PMID: 29740072
Int J Cancer

Targeting FAK scaffold functions inhibits human renal cell carcinoma growth. [Abstract]

2015 Oct 1;137(7):1549-59. PMID: 25809490

PF-562271 purchased from MedChemExpress. Usage Cited in: Int J Cancer. 2015 Oct 1;137(7):1549-59. [Abstract]

786-O (a) and Caki-1 (b) are treated for 24 and 48h with increasing concentrations of PF-562,271 and adherent cells were counted. Cell lysates are evaluated through immunoblotting for total FAK following treatment for 24h.
Cell Signal

Tenvermectin B, a novel macrocyclic lactone antibiotic, suppresses glioblastoma progression by targeting RhoJ. [Abstract]

2025 Sep 10:136:112117. PMID: 40939916
Environ Toxicol Pharmacol

ZC3H4 Governs Epithelial Cell Migration through ROCK/p-PYK2/p-MLC2 Pathway in Silica-induced Pulmonary Fibrosis. [Abstract]

2023 Nov:104:104301. PMID: 37866415
Eur J Cell Biol

The mechanical mechanism of angiotensin II induced activation of hepatic stellate cells promoting portal hypertension. [Abstract]

2024 May 28;103(2):151427. PMID: 38820882
Cancer Med

Focal Adhesion Kinase Intersects With the BRD4-MYC Axis and YAP1 to Drive Tumor Cell Growth, Phenotypic Plasticity, Stemness, and Metastatic Potential in Colorectal Cancer. [Abstract]

2025 Sep;14(18):e71227. PMID: 40959971
Mol Biol Rep

Piperlongumine inhibits the proliferation and migration of non-small cell lung cancer cells through the EGFR/FAK/STAT3 pathway. [Abstract]

2026 May 14;53(1):770. PMID: 42133146
Mol Biol Rep

Ginkgetin inhibits the proliferation and migration of lung cancer cells via FAK/STAT3/AKT pathway. [Abstract]

2025 May 14;52(1):458. PMID: 40366441
J Nat Med

Antiangiogenic effects of AG36, a triterpenoid saponin from Ardisia gigantifolia stapf. [Abstract]

2020 Sep;74(4):732-740. PMID: 32643027
Anticancer Drugs

AZD7762 induces CRBN dependent BAG3 degradation through ubiquitin-proteasome pathway. [Abstract]

2024 Jan 1;35(1):46-54. PMID: 37449977
Res Sq

2025 Jul 11.
University of Washington

2025.
bioRxiv

2025 May 28.
bioRxiv

FAK Differentially Mechanoregulates Cell Migration During Wound Closure. [Abstract]

2025 Apr 7:2025.04.01.646098. PMID: 40291676
Research Square Preprint

2023 May 23.
Research Square Preprint

2021 Dec.
Practical Oncology Journal

2015, 29(5): 444-449.

PF-562271 purchased from MedChemExpress. Usage Cited in: Practical Oncology Journal. 2015, 29(5): 444-449.

Effects and mechanism of Biglycan and FAK signaling pathway on the invasion and metastasis of colon cancer cells.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 66.67 mg/mL (131.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9705 mL

9.8524 mL

19.7048 mL

5 mM

0.3941 mL

1.9705 mL

3.9410 mL

10 mM

0.1970 mL

0.9852 mL

1.9705 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.67 mg/mL (3.29 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.67 mg/mL (3.29 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Roberts WG, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer research. 2008 Mar 15;68(6):1935-44. [Content Brief]

[2]. Stokes JB, et al. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Molecular cancer therapeutics. 2011 Nov;10(11):2135-45. [Content Brief]

[3]. Bagi CM, et al. Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model. Cancer biology & therapy. 2009 May;8(9):856-65. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9705 mL	9.8524 mL	19.7048 mL	49.2621 mL
	5 mM	0.3941 mL	1.9705 mL	3.9410 mL	9.8524 mL
	10 mM	0.1970 mL	0.9852 mL	1.9705 mL	4.9262 mL
	15 mM	0.1314 mL	0.6568 mL	1.3137 mL	3.2841 mL
	20 mM	0.0985 mL	0.4926 mL	0.9852 mL	2.4631 mL
	25 mM	0.0788 mL	0.3941 mL	0.7882 mL	1.9705 mL
	30 mM	0.0657 mL	0.3284 mL	0.6568 mL	1.6421 mL
	40 mM	0.0493 mL	0.2463 mL	0.4926 mL	1.2316 mL
	50 mM	0.0394 mL	0.1970 mL	0.3941 mL	0.9852 mL
	60 mM	0.0328 mL	0.1642 mL	0.3284 mL	0.8210 mL
	80 mM	0.0246 mL	0.1232 mL	0.2463 mL	0.6158 mL
	100 mM	0.0197 mL	0.0985 mL	0.1970 mL	0.4926 mL

Bioz

PF-562271

32 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

PF-562271

Defactinib

PF-573228

PND-1186

GSK2256098

Dasatinib

Verteporfin

PF-431396

NVP-TAE 226

Y15

PF-4618433

Trametinib

Simvastatin

Publications Citing Use of MedChemExpress (MCE) PF-562271

Biologische Aktivität

Chemical Information

Publications (32)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

PF-562271

Defactinib

PF-573228

PND-1186

GSK2256098

Dasatinib

Verteporfin

PF-431396

NVP-TAE 226

Y15

PF-4618433

Trametinib

Simvastatin

Publications Citing Use of MedChemExpress (MCE) PF-562271

Biologische Aktivität

Chemical Information

Publications (32)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

PF-562271 Related Classifications

HY-10459 Related Classifications

Bioz